Relief Therapeutics Files Amendment No. 4 to its Registration Statement on Form 20-F with the United States Securities and Exchange Commission

GENEVA, SWITZERLAND / ACCESSWIRE / July 4, 2022 / RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) (“ Relief “), today announced that it has filed Amendment No. 4 to its registration statement on Form 20-F (“ Registration statement “) with the United States Securities and Exchange Commission (“ SECOND “). The registration statement is intended to register Relief as a reporting company under the Securities Exchange Act of 1934. The registration statement was filed as part of an ongoing program to convert the certificate Relief’s Tier 1 U.S. Repository (“ ADR “) program in the United States to a Tier 2 ADR program, and is part of Relief’s ongoing efforts to list its ADRs on the NASDAQ stock exchange. Listing on NASDAQ will not occur until after effective of the Registration Statement, which is subject to ongoing review of the Registration Statement by the SEC and Relief’s filing for listing on NASDAQ (which has not yet occurred). There can be no assurance that the Registration Statement will become effective or that Relief will be successful in its efforts to list its ADRs on the NASDAQ stock market.

Relief Therapeutics Holdings AG, Monday, July 4, 2022, press release photo

The filing of the registration statement does not form part of an offer of securities. Therefore, Relief will not receive any proceeds from its current ADR program.

This press release is not intended to and does not constitute an offer to sell or the solicitation of an offer to buy securities in the United States or any other jurisdiction, and there will be no offer or sale of securities in the United States or in any other jurisdiction in which such offer, solicitation or sale would be unlawful unless registered and/or qualified under applicable securities laws. This press release does not constitute a prospectus within the meaning of art. 35 of the Federal Financial Services Act of June 15, 2018, as amended (“FinSA”), or art. 27 et seq. listing rules of the SIX Swiss Exchange. There is no intention or authorization to publicly offer, solicit, sell or advertise, directly or indirectly, Relief titles in or to Switzerland within the meaning ofLSFinSA. Further, the ADRs have not been registered under the Securities Act of 1933, as amended (the “Act”), and no public offering of securities shall be made in the United States except through a prospectus made available by Relief which contains detailed information about Relief and its management, as well as financial statements meeting the requirements of the law.


Relief primarily focuses on clinical-stage programs based on molecules with a history of clinical trials and use in human patients or strong scientific rationale. Relief has also entered into a collaboration and licensing agreement with Acer Therapeutics for the development and worldwide commercialization of ACER-001 (sodium phenylbutyrate) for the treatment of inborn errors of metabolism, including metabolic disorders. urea cycle and maple syrup urinary disease. Relief is also continuing to study aviptadil for several possible lung conditions. Finally, Relief’s 2021 acquisitions of APR Applied Pharma Research SA and AdVita Lifescience GmbH have provided Relief with a diverse pipeline of commercialized and development-stage programs.

RELIEF THERAPEUTICS Holding SA is listed on the SIX Swiss Exchange under the symbol RLF and listed in the United States on the OTCQB under the symbols RLFTF and RLFTY.

For more information, visit Follow us on LinkedIn.

Jack Weinstein
Financial Director and Treasurer
[email protected]

Rx Communications Group
Michael Miller
[email protected]

Disclaimer: This communication expressly or implicitly contains certain forward-looking statements regarding RELIEF THERAPEUTICS Holding SA and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, including (i) whether the registration statement will become effective, (ii) whether a market will develop for Relief’s ADRs, (iii) whether, if Relief’s ADRs are traded on the in the United States, they will become eligible to be listed on the NASDAQ stock market, and the timing of such listing, and (iv) the risks discussed in filings by RELIEF THERAPEUTICS Holding SA with SIX Swiss Exchange, press releases and filings with the SEC, which could cause the actual results, financial condition, performance or achievements of RELIEF THERAPEUTICS Holding SA to differ materially from future results, performance or achievements expressed or implied by these forward-looking statements. RELIEF THERAPEUTICS Holding SA is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

THE SOURCE: Relief Therapeutics Holdings SA

See the source version on Foreign exchange fee

Comments are closed.